Name | Number of supported studies | Average coverage | |
---|---|---|---|
capillary endothelial cell | 5 studies | 21% ± 3% | |
endothelial cell | 5 studies | 27% ± 11% | |
epithelial cell | 5 studies | 31% ± 9% | |
endothelial cell of artery | 4 studies | 19% ± 3% | |
glomerular endothelial cell | 3 studies | 19% ± 2% | |
ciliated cell | 3 studies | 21% ± 4% | |
goblet cell | 3 studies | 21% ± 2% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
liver | 3 studies | 25% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
ovary | 100% | 668.68 | 180 / 180 | 100% | 33.37 | 430 / 430 |
brain | 100% | 728.80 | 2640 / 2642 | 100% | 27.90 | 705 / 705 |
uterus | 100% | 662.20 | 170 / 170 | 99% | 31.90 | 455 / 459 |
liver | 100% | 965.01 | 226 / 226 | 99% | 35.32 | 402 / 406 |
bladder | 100% | 526.05 | 21 / 21 | 99% | 31.53 | 497 / 504 |
skin | 100% | 459.00 | 1806 / 1809 | 99% | 28.45 | 466 / 472 |
prostate | 99% | 547.98 | 243 / 245 | 99% | 25.26 | 498 / 502 |
intestine | 100% | 662.29 | 966 / 966 | 98% | 44.23 | 518 / 527 |
thymus | 98% | 478.48 | 643 / 653 | 99% | 23.66 | 598 / 605 |
stomach | 100% | 452.21 | 359 / 359 | 97% | 35.04 | 278 / 286 |
adrenal gland | 99% | 405.64 | 256 / 258 | 98% | 19.67 | 225 / 230 |
lung | 99% | 546.09 | 570 / 578 | 98% | 24.85 | 1132 / 1155 |
breast | 100% | 511.08 | 457 / 459 | 97% | 27.73 | 1084 / 1118 |
esophagus | 100% | 476.37 | 1439 / 1445 | 95% | 12.98 | 174 / 183 |
pancreas | 97% | 253.03 | 317 / 328 | 97% | 24.26 | 172 / 178 |
kidney | 99% | 414.96 | 88 / 89 | 89% | 13.50 | 806 / 901 |
eye | 0% | 0 | 0 / 0 | 100% | 25.51 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 41.88 | 29 / 29 |
spleen | 100% | 781.91 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 22.24 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 39.10 | 1 / 1 |
blood vessel | 99% | 517.19 | 1327 / 1335 | 0% | 0 | 0 / 0 |
adipose | 99% | 479.83 | 1193 / 1204 | 0% | 0 | 0 / 0 |
heart | 98% | 359.21 | 843 / 861 | 0% | 0 | 0 / 0 |
muscle | 91% | 203.39 | 734 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 74% | 287.60 | 683 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006289 | Biological process | nucleotide-excision repair |
GO_0006285 | Biological process | base-excision repair, AP site formation |
GO_0045008 | Biological process | depyrimidination |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0005634 | Cellular component | nucleus |
GO_0003906 | Molecular function | DNA-(apurinic or apyrimidinic site) endonuclease activity |
GO_0003690 | Molecular function | double-stranded DNA binding |
GO_0004519 | Molecular function | endonuclease activity |
GO_0140078 | Molecular function | class I DNA-(apurinic or apyrimidinic site) endonuclease activity |
GO_0008534 | Molecular function | oxidized purine nucleobase lesion DNA N-glycosylase activity |
GO_0019104 | Molecular function | DNA N-glycosylase activity |
GO_0005515 | Molecular function | protein binding |
GO_0003684 | Molecular function | damaged DNA binding |
GO_0051539 | Molecular function | 4 iron, 4 sulfur cluster binding |
GO_0000703 | Molecular function | oxidized pyrimidine nucleobase lesion DNA N-glycosylase activity |
GO_0046872 | Molecular function | metal ion binding |
Gene name | NTHL1 |
Protein name | Nth like DNA glycosylase 1 Endonuclease III-like protein 1 (hNTH1) (EC 3.2.2.-) (EC 4.2.99.18) (Bifunctional DNA N-glycosylase/DNA-(apurinic or apyrimidinic site) lyase) (DNA glycosylase/AP lyase) DNA-(apurinic or apyrimidinic site) lyase (EC 4.2.99.18) Endonuclease III-like protein 1 (EC 3.2.2.-) (EC 4.2.99.18) (Bifunctional DNA N-glycosylase/DNA-(apurinic or apyrimidinic site) lyase) (DNA glycosylase/AP lyase) |
Synonyms | hCG_1989994 NTH1 OCTS3 |
Description | FUNCTION: Bifunctional DNA N-glycosylase with associated apurinic/apyrimidinic (AP) lyase function that catalyzes the first step in base excision repair (BER), the primary repair pathway for the repair of oxidative DNA damage . The DNA N-glycosylase activity releases the damaged DNA base from DNA by cleaving the N-glycosidic bond, leaving an AP site. The AP-lyase activity cleaves the phosphodiester bond 3' to the AP site by a beta-elimination. Primarily recognizes and repairs oxidative base damage of pyrimidines. Has also 8-oxo-7,8-dihydroguanine (8-oxoG) DNA glycosylase activity. Acts preferentially on DNA damage opposite guanine residues in DNA. Is able to process lesions in nucleosomes without requiring or inducing nucleosome disruption. . FUNCTION: Bifunctional DNA N-glycosylase with associated apurinic/apyrimidinic (AP) lyase function that catalyzes the first step in base excision repair (BER), the primary repair pathway for the repair of oxidative DNA damage. The DNA N-glycosylase activity releases the damaged DNA base from DNA by cleaving the N-glycosidic bond, leaving an AP site. The AP lyase activity cleaves the phosphodiester bond 3' to the AP site by a beta-elimination. Primarily recognizes and repairs oxidative base damage of pyrimidines. . |
Accessions | ENST00000651570.2 [P78549-2] ENST00000561841.1 A0A494BZZ6 E5KTI5 P78549 ENST00000651583.1 ENST00000651522.1 ENST00000566380.5 H3BPD5 A0A494C106 ENST00000219066.5 [P78549-1] H3BUV2 ENST00000568513.5 H3BRL9 |